Абстрактный

Biochemical alterations in hepatocellular carcinoma patients treated with doxorubicin

Saber A.Sakr, Nahed S.Bassely, Mona A.Sakr, Mahmoud Moawad, Hassan M.Ahmed

Doxorubicin (Dox) is an anthracycline antibiotic used as a single chemotherapeutic agent for HCC and has been shown to produce a response rate of about 10-15% but with no proven survival benefits. The present work was conducted to study the biochemical alterations in HCC patients treated with doxorubicin. The study included 30 patients with a confirmed diagnosis of hepatocellular carcinoma (HCC). They were divided into 3 groups. Group 1.Ten specimens of heptocellular carcinoma patients were taken before doxorubicin treatments. Group 2.Ten specimens of heptocellular carcinoma patients were taken one week after doxorubicin treatment. Group 3.Ten specimens of heptocellular carcinoma patientswere taken two weeks after doxorubicin treatment. Another ten normal volunteers were used as controls. Treatment schedule consists of i.v. injection of doxorubicin at a dose of 15 mg/m2 weekly for 3 weeks.Ascitic fluid and blood serum were collected for biochemical examinations. The results showed that asciticAFP, CEA, T.LDH and LDH4, LDH5 increased significantly inHCC patients.ALT,AST andALP showed significant increase in sera of HCC patients. These biochemical parameters revealed significant decrease in Dox treated patients.